Rezolute, Inc. (RZLT)
Develops a treatment to prevent dangerous low blood sugar in children with a rare genetic disorder
$4.92-0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-16.2%
The outlook
RZLT is trading above both its 50- and 200-day moving averages, sitting in the lower portion of its 52-week range. Analyst coverage leans bullish with an average price target about 56% above the current price, suggesting meaningful upside relative to where shares trade today.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range37% of the way from its 52-week low to high
Price targetAvg target +56% vs current price
Analyst price target
~12-month · 9 analysts$7.67average target+55.8% vs now
Now $4.92
Low $4.00High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$473.8M
52-wk high
$11.46
52-wk low
$1.07
50-day avg
$4.37
200-day avg
$4.79
Trailing P/E
—